GRIFOLS, S.A. 04/07/2019 15:15 GRIFOLS, S.A. R&D: new licenses, patents and registered trademarks The U.S. Food and Drug Administration has approved Grifols´ new 20% subcutaneous immunoglobulin product, Xembify®, which is used to treat primary immunodeficiencies. Número de registro: 279882